Hims & Hers Debuts Compounded Wegovy Alternative, Faces Novo Nordisk Lawsuit Threat
Telehealth provider Hims & Hers introduced a compounded semaglutide injection version of Wegovy on Feb. 7, offering patients a lower-cost alternative to Novo Nordisk’s patented obesity treatment. Novo Nordisk has issued a legal threat over potential patent infringement, raising litigation risks for Hims & Hers operations.
1. Launch of Compounded Semaglutide
On Feb. 7, Hims & Hers began offering a compounded version of semaglutide, mirroring the active ingredient in Wegovy, through its network of compounding pharmacies. The company positions this product as a lower-priced alternative to the branded obesity treatment, targeting budget-conscious weight-loss patients.
2. Novo Nordisk Patent Threat
Shortly after the launch, Novo Nordisk alerted Hims & Hers that compounding semaglutide infringes on its patents covering Wegovy’s formulation and delivery method. The Danish drugmaker has warned of legal action if the compounded product continues to be marketed.
3. Potential Financial Impact
Hims & Hers may face significant legal expenses and potential damages if a lawsuit proceeds, which could strain its cash flow and divert resources from growth initiatives. Conversely, the alternative offering could boost subscription numbers if litigation is avoided or resolved favorably.